On July 22, 2024 Epigenomics AG (FSE: ECX; ISIN: DE000A37FT41) reported that it has closed its first half of the 2024 fiscal year (January 1 to June 30, 2024) with an expected loss (individual financial statements according to the German Commercial Code) of EUR 0.8 million (comparable period 1H 2023 ("H1"): loss EUR 5.7 million) and with freely available liquid funds (consisting of cash and bank balances) of EUR 1.2 million as of June 30, 2024 (previous year December 31, 2023 ("previous year"): EUR 2.1 million) (Press release, Epigenomics, JUL 22, 2024, View Source [SID1234645001]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The preliminary result includes other operating income of EUR 78 thousand (previous year: EUR 438 thousand), as well as personnel expenses of EUR 233 thousand (previous year: EUR 3,502 thousand), other operating expenses of EUR 465 thousand (previous year: EUR 2,575 thousand) and a financial result of EUR -164 thousand (previous year: EUR 306 thousand), mainly consisting of depreciation on financial assets of EUR 178 thousand (previous year: EUR 0 thousand).

Other operating expenses mainly include legal and consulting costs (EUR 152 thousand), costs of stock exchange listing and capital market communication (EUR 97 thousand), IT costs (EUR 62 thousand) and accounting and auditing costs (EUR 56 thousand).

The preliminary balance sheet as of June 30, 2024 according to the German Commercial Code (HGB) shows negative equity of EUR 8,344 thousand (previous year: negative equity EUR 8,016 thousand).

In the forecast report of the last annual financial statements (financial year 2023), the Management Board forecast an annual result in the range of EUR -1.2 million to EUR -0.8 million for the financial year 2024. The Management Board is currently sticking to the existing forecast for the financial year 2024.

The above-mentioned preliminary result is based on the preliminary assessment of the first half of 2024 carried out by the Management Board on July 22, 2024.